Regeneron ' s Anti-Blindness Drug Approved for Less Frequent Treatments Regeneron ' s Anti-Blindness Drug Approved for Less Frequent Treatments

Regeneron said on Friday it had won U.S. Food and Drug Administration approval for less-frequent applications of its Eylea (aflibercept) anti-blindness treatment, which may come under pressure from a rival product made by Novatis.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news